LumaCyte - About the company
LumaCyte is a series B company based in Charlottesville (United States), founded in 2012. It operates as a Provider of microfluidic and optics based instruments. LumaCyte has raised $24.1M in funding from Malvern Panalytical. The company has 56 active competitors, including 17 funded and 8 that have exited. Its top competitors include companies like NanoCellect Biomedical, Cell Microsystems and nanoMR.
Company Details
Provider of microfluidic and optics based instruments. The company's proprietary product Radiance is a label-free microfluidic cell analyzer and sorter that allows characterization and sorting of individual cells by measuring their optical force and it has tremendous application for vaccine development in both R&D and manufacturing including viral infectivity assays. The ability to automate data collection on the viral infectivity of cells while improving results, reducing cost and time is invaluable for developing and producing vaccines.
- Website
- www.lumacyte.com/
- Email ID
- *****@lumacyte.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2012
Location
Charlottesville, United States
Stage
Series B
Total Funding
$24.1M in 8 rounds
Latest Funding Round
Investors
Ranked
2nd among 56 active competitors
Employee Count
24 as on Sep 30, 2026
Similar Companies
Legal entities associated with LumaCyte
LumaCyte is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Lumacyte, Llc CIN: 1589470 , United States, Active | $1 - $1M (As on May 09, 2014) | - | - | |
LumaCyte, Inc. CIN: 1589470 , United States, Active | $5M - $25M (As on May 17, 2022) | - | - |
Sign up to download LumaCyte's company profile
LumaCyte's funding and investors
LumaCyte has raised a total funding of $24.1M over 8 rounds. Its first funding round was on May 09, 2014. Its latest funding round was a Series B round on Sep 06, 2023 for $*****. 1 investor participated in its latest round. LumaCyte has 2 institutional investors.
Here is the list of recent funding rounds of LumaCyte:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 06, 2023 | 5486916 | Series B | 1305237 | 4537453 | 3585014 | 5715654 |
Mar 02, 2022 | 3407874 | Series A | 6041613 | 7034476 | 8216907 | 1904066 |
Jan 04, 2021 | 6824843 | Seed | 3324278 | 3996965 | 7854481 | 3028236 |
View details of LumaCyte's funding rounds and investors
LumaCyte's founders and board of directors
Founder? Claim ProfileLumaCyte's employee count trend
LumaCyte has 24 employees as of Sep 26. Here is LumaCyte's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
LumaCyte's Competitors and alternates
Top competitors of LumaCyte include NanoCellect Biomedical, Cell Microsystems and nanoMR. Here is the list of Top 10 competitors of LumaCyte, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | NanoCellect Biomedical 2009, San Diego (United States), Series D | Develops flow cytometry and cell sorting technology | $78.1M | 59/100 | |
2nd | LumaCyte 2012, Charlottesville (United States), Series B | Provider of microfluidic and optics based instruments | $24.1M | 54/100 | |
3rd | Cell Microsystems 2009, Durham (United States), Series B | Developer of a technology to isolate and recover single cells for molecular analysis | $19.1M | 51/100 | |
4th | nanoMR 2006, Albuquerque (United States), Acquired | Developed the system for rapid isolation of rare cells | $25.5M | 50/100 | |
5th | Developer of cell sorting and single cell profiling platforms | $83.2M | 49/100 | ||
6th | Single Cell Discoveries 2018, Utrecht (Netherlands), Unfunded | Provider of single-cell sequencing-based instrument and services | - | - | 46/100 |
7th | Immunicon 1983, Bryn Athyn (United States), Acquired | Cell and molecular-based human diagnostic and life science research products for cancer disease management | $75.4M | 44/100 | |
8th | Silicon Biosystems 1999, Bologna (Italy), Acquired | Developer of lab on a chip technologies for miniaturized cell-biology testing | $25.5M | 44/100 | |
9th | Cytomos 2012, Edinburgh (United Kingdom), Series A | POC cell sorter | $13.6M | 44/100 | |
10th | Cellular Highways 2016, Melbourn (United Kingdom), Acquired | Developer of cell sorting device | - | - | 43/100 |
Looking for more details on LumaCyte's competitors? Click here to see the top ones
LumaCyte's Investments and acquisitions
LumaCyte has made no investments or acquisitions yet.
Reports related to LumaCyte
Here is the latest report on LumaCyte's sector:
News related to LumaCyte
Media has covered LumaCyte for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
Second Global ISO Standard Expands LumaCyte Measurement Framework to Mammalian Cell ViabilityBusiness Wire•Jun 02, 2026•LumaCyte
•
LumaCyte Analytical Method Included in Newly Published ISO Global Standard for Viral Vector QuantificationBusiness Wire•Mar 31, 2026•LumaCyte
•
LumaCyte Unveils Predictive CAR T Donor Analytics to Revolutionize Cell Therapy ManufacturingBusiness Wire•Sep 04, 2024•LumaCyte
•
LumaCyte Launches Laser Force Cytology™ Academy after Training FDA ReviewersBusiness Wire•Jul 30, 2024•LumaCyte
•
LumaCyte Launches New Compact Radiance® Instrument for Advanced Therapy Biomanufacturing & QC EnvironmentsBusiness Wire•Oct 24, 2023•LumaCyte
•
LumaCyte has filed a notice of an exempt offering of securities to raise $12,999,991.00 in New Equity Investment.https://www.intelligence360.news/•Sep 28, 2023•LumaCyte, SEC
•
LumaCyte Accelerates Global Growth, Closing Strategic Series B FinancingBusiness Wire•Sep 06, 2023•LumaCyte, Malvern Panalytical
•
LumaCyte Fueled for Growth, Names Top Life Sciences Industry Executives to BoardBusiness Wire•Mar 08, 2022•LumaCyte, Catalent
•
LumaCyte Appoints Vaccine Manufacturing Expert to Scientific Advisory BoardBusiness Wire•Apr 20, 2021•LumaCyte, CEPI
•
LumaCyte Expands Into Europe Tackling Expansive Vaccine and Cell and Gene Therapy MarketsCMOCRO•Feb 20, 2020•LumaCyte
Are you a Founder ?
FAQs about LumaCyte
Explore our recently published companies
- Linum - Kuurne based, 1983 founded, Unfunded company
- Industrialex Manufacturing - Arvada based, 1994 founded, Unfunded company
- Inphosoft - Singapore based, 2002 founded, Unfunded company
- IMPLASER - Alfajarin based, 1999 founded, Funding Raised company
- HubLink - San Diego based, 2022 founded, Funding Raised company
- Bluechip crypto currency - Funding Raised company